The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
Admin
One Missed, One Published the Arm That Failed, One Disclosed a Verb
Three Phase 3 toplines in one day, and the detail released runs inversely to the strength of the result. One company disclosed no number at all.
Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four
CI Neurology/Medtech/Neuromodulation Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four Athithi Verma· 21 July 2026· 1 min read· Synopulse Biotronik Neuro launched Embrace One on 20 July, an AI capability for its Prospera spinal cord stimulation (SCS) system. It analyses more than 200 remote-monitoring data points per patient per day to flag … Read more
Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold
Deal Oncology/ Diagnostics/ MRD Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold Athithi Verma· 21 July 2026· 1 min read· Synopulse Tempus AI will acquire Personalis at $16.25 per share, a $1.5B enterprise value net of the stake Tempus already held. All-stock, with a cash option capped at 50 percent. … Read more